



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

6 July 2023
EMA/168978/2023

Agenda – 10th Industry stakeholder platform on research and development support

11 July 2023, 12:30 – 17:30 (room 1D)

Chair: Michael Berntgen

Item	Agenda	Time
1.	Welcome / Introductions • Overview of the agenda • Review of status of follow-up actions from the last platform meeting <i>Michael Berntgen, EMA</i>	10 min
2.	Update on latest developments in scientific advice • Summary of revised guidance • Volume and capacity of the scientific advice offering • Initiatives to progress towards integrated scientific dialogue • Feedback from developers <i>Iordanis Gravanis (EMA)</i> <i>Bertrand Fournier (EUCOPE) and Esteban Herrero-Martinez (EFPIA)</i>	30 min
3.	Progress with the implementation of the recommendations to further strengthen the PRIME scheme • Status of implementation activities and first experiences (expedited scientific advice, development tracker / roadmap, submission readiness meetings) • First experiences from developers' perspective <i>Kevin Cunningham and Anna Gross (EMA)</i> <i>Nadege Le Roux (EFPIA)</i>	40 min
4.	Report from the multi-stakeholder workshop on qualification of novel methodologies • Summary of the workshop outcome • Next steps to strengthen the process for qualification <i>Thorsten Vetter (EMA)</i> <i>Mireille Mueller (EFPIA)</i>	20 min

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Item	Agenda	Time
5.	Cooperation at the HTA/regulatory interface - Update from the parallel consultations under EUnetHTA 21 - Consultation opportunities during the transition phase - Feedback from developers <i>Thorsten Olski (EMA) and Stephanie Said (EUnetHTA21)</i> <i>Claudine Sapede (EFPIA)</i>	30 min
	Coffee break	20 min
6.	Progress with the implementation of initiatives to optimise the application of the PIP framework - Experience with the stepwise PIP (sPIP) concept - Revision of the Key elements and the Summary report template - Feedback from developers <i>Chrissi Pallidis (EMA) and Sabine Scherer (BfArM, PDCO)</i> <i>Marcello Milano (EuropaBio)</i>	40 min
7.	Development of complex generics - Challenges from a developers' perspective - Recent initiatives by EMA <i>Parminder Kaur (EuropharmSMC) and Susana Almeida (Medicines for Europe)</i> <i>Kevin Blake (EMA)</i>	20 min
8.	Report from the Focus group on provision of scientific advice for medicinal product developments comprising of drug-device combinations and drug-companion diagnostic combinations - Analysis of scientific questions on medicinal product development in combination with medical devices or companion diagnostics to be addressed in scientific advice <i>Alexa Hunter (EuropaBio) and Tim Chesworth (EFPIA)</i> <i>Sheila Killalea (HPRA, SAWP) and Ilona Reischl (AGES)</i> - Limitations for engagement by Notified Bodies <i>Alex Laan (BSI)</i> - Medicinal product/Medical device interfaces: NCA challenges <i>Ilona Reischl (AGES)</i> - Proposals moving forward to facilitate the scientific dialogue within the current regulatory framework and potentially in the future <i>Stiina Aarum (EMA)</i>	80 min
9.	Summary of follow-up items / Close of the meeting <i>Michael Berntgen, EMA</i>	5 min